Science 37 Blockbuster SPAC Valuation Points To Growth In Decentralized Trials
Expanding partnerships with CROs, the COVID-19 lockdown, an eager FDA and an industry desire for faster and more diverse clinical trial recruiting helped Science 37, a decentralized clinical trial company, nail down plans to go public. Science 37 CEO David Coman spoke with In Vivo about the reasons for going public via SPAC, and why decentralization is a “prerequisite to operating a clinical trial today.”
You may also be interested in...
Venture capitalists and industry executives discussed strategies for placing smart bets on emerging gene therapy companies during a recent virtual panel.
Despite the COVID-19 chaos felt by many industries in 2020, biopharma IPOs recorded a banner year – including a marked rise in the use of special purpose acquisition companies (SPACs), also known as blank check companies.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.